Mystic Asset Management Inc. grew its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 8.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 338,902 shares of the company's stock after purchasing an additional 25,555 shares during the quarter. Mystic Asset Management Inc. owned approximately 0.62% of Zevra Therapeutics worth $2,538,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Woodline Partners LP raised its stake in Zevra Therapeutics by 2.2% during the fourth quarter. Woodline Partners LP now owns 4,139,593 shares of the company's stock worth $34,524,000 after purchasing an additional 90,940 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of Zevra Therapeutics by 462.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company's stock valued at $30,441,000 after acquiring an additional 3,001,000 shares during the period. Vanguard Group Inc. raised its stake in shares of Zevra Therapeutics by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company's stock valued at $23,554,000 after acquiring an additional 68,151 shares during the period. Altium Capital Management LLC raised its stake in shares of Zevra Therapeutics by 8.8% in the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company's stock valued at $15,429,000 after acquiring an additional 150,000 shares during the period. Finally, Geode Capital Management LLC increased its stake in Zevra Therapeutics by 13.8% during the 4th quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company's stock worth $9,912,000 after buying an additional 144,256 shares during the period. Institutional investors and hedge funds own 35.03% of the company's stock.
Zevra Therapeutics Stock Up 0.0%
Shares of NASDAQ:ZVRA opened at $12.32 on Thursday. The stock has a market cap of $673.71 million, a P/E ratio of -6.48 and a beta of 1.97. The firm has a fifty day moving average price of $9.36 and a 200 day moving average price of $8.29. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.02 and a quick ratio of 2.93. Zevra Therapeutics, Inc. has a 1-year low of $5.45 and a 1-year high of $13.16.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The company had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same quarter in the prior year, the firm earned ($0.40) EPS. Sell-side analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on ZVRA. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Cantor Fitzgerald upped their target price on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. Wall Street Zen upgraded shares of Zevra Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 12th. Finally, HC Wainwright initiated coverage on shares of Zevra Therapeutics in a report on Wednesday, July 2nd. They set a "buy" rating and a $26.00 price target for the company. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $23.71.
Read Our Latest Analysis on Zevra Therapeutics
About Zevra Therapeutics
(
Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Featured Articles
Want to see what other hedge funds are holding ZVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
